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Background: Anemia is a common problem in HIV (human immunodeficiency virus) infected patients, and is
associated with decreased functional capacity and quality of life. Ethiopia is one of the countries which has
expanded highly active antiretroviral treatment (HAART) over the past years. The effect of HAART on anemia among
HIV remains inconsistent and inconclusive, particularly in children. This study thus aimed to synthesize the
prevalence of anemia among HIV infected Ethiopian children and its association with HAART initiation.
Methods: MEDLINE/PubMed, EMBASE, PsycINFO, Web of Science and Google scholar were used to identify 12
eligible studies reporting an association between anemia and HIV using a priori set criteria. PRISMA guideline was
used to systematically review and meta-analysis these studies. Details of sample size, magnitude of effect sizes,
including odds ratio (OR) and standard errors were extracted. Random-effects model was used to calculate the
pooled estimates using STATA/SE version-14. I2 and meta-bias statistics assessed heterogeneity and publication bias
of the included studies. Sub-group analyses, based on study designs, were also carried out.
Results: In Ethiopia, the overall prevalence of anemia in HIV infected children was 22.3% (95% CI: 18.5–26.0%). The
OR of anemia-HIV/AIDS comorbidity was 0.4 (95% CI, 0.2–0.5) in HAART initiated children as compared to non-
initiated counterparts. Meta-bias and funnel plot detected no publication bias.
Conclusion: On aggregate, anemia is a common comorbidity in pediatric HIV patients. HAART was significantly
associated with a reduced anemia-HIV/AIDS comorbidity. Prompt start of HAART might help decreasing the
prevalence of anemia and its subsequent complications.
Keywords: HAART, Children, Systematic review, Meta-analysis, Prevalence, Epidemiology, Human immunodeficiency
virus, HIV, Ethiopia, Comorbidity, Iron status, AnemiaBackground
Anemia has substantial negative effects on the health and
economic wellbeing of nations and communities. Children
with anemia experience irrevocable cognitive and develop-
mental delays and exhibit decreased work related product-
ivity as adults [1]. Anemia among HIV infected children is
an emerging public health problem. A quarter of the global
population suffer from anemia, including 293 million (47%)
children younger than 5 years [2] whereby more than 100
million of these anemic children live in Africa [3]. Ethiopia© The Author(s). 2019 Open Access This artic
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In Ethiopia, over 90% of new HIV infected children ac-
quire the virus through vertical transmission. Of the esti-
mated incidence of HIV infections, children account 13% of
the estimated total HIV positive population in 2014 [4]. A
systematic review and meta-analysis done in Ethiopia re-
ports 9.93% pooled prevalence of mother-to-child-transmis-
sion (MTCT) of HIV [5]. Also, previous study conducted in
southern Ethiopia shows a 4.2% HIV positive rate in infants,
of whom 2.6% were born from mothers who were on pre-
ventive MTCT intervention [6]. This may indicate that the
magnitude of MTCT has not significantly reduced, and thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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merous challenges. That said, the government of Ethiopia
has scaled up its efforts to hastily decline and subsequently
eliminate MTCT and apprehend the vision of HIV free,
new generation by 2020. In addition, the Ethiopian Federal
Ministry of Health (FMoH) has employed option B+ (test-
and-treat) prevention of mother-to-child-transmission
(PMTCT), an approach to avoid new HIV infection in new-
borns. According to option B+, all HIV infected women
should be initiated on ART as soon as possible regardless
of gestational age, CD4 count and clinical stage, and should
be continued the treatment for the rest of their lives. Also,
the preferred first line ART regimen for children is AZT or
ABC+ 3TC+ EFV and the alternative first line ART regi-
men is AZT+ 3TC+NVP or TDF + 3TC+ EFV [7].
Hematological complications have been documented to
be the second most common cause of morbidity and mor-
tality among HIV positive children [8]. Indeed, anemia is a
common and serious complication of both HIV infection
and its treatment. That is, anemia is recognized as a major
hematologic complication and has a significant impact on
children’s survival, treatment outcomes and quality of life
[9]. This involves a serum hemoglobin concentration of <
11 g/dl for pediatrics age group or that < 4.0 g/dl in very
severe cases [10, 11].
In general, multi-factorial causes contribute to the in-
crease in the burden of anemia among HIV patients. Some
include opportunistic infections, change in immune system
adaptability, nutritional deficiencies and side effects of
HAART drugs including bone marrow suppression by
HAART. Other common causes of anemia in HIV are
chronic diseases, and hemolytic anemia induced by oxidant
drugs. HIV infection itself can also cause anemia, perhaps
as a consequence of HIV infection of stromal cells [12, 13].
Although HAART is capable of reducing the incidence of
anemia [14–17] through enhancing CD4 cell count and
suppressing viral duplication, it can also cause anemia. For
instance, cotrimoxazole, pentamidine and zidovudine often
argued to be associated with reticuloendothelial iron block
[18, 19]. Cytokines such as interleukin 1, tumor necrosis
factor and the interferon play a role in impairing erythro-
poietin response by reducing concentration of marrow pro-
genitors and erythroid colonies. Zidovudine is widely used
drug that results in myelosuppression causing anemia [12].
In the same vein, although HAART has been associated
with a decrease in the incidence and severity of anemia, re-
cent evidence shows that a decrease in hemoglobin level
still occurs and is a predictors of poor clinical outcome.
Moreover, according to EDHS 2016 reports, 57% of
children age 6–59months suffered from some degree of
anemia (hemoglobin levels below 11 g/dl). Twenty-five
percent of children are classified with mild anemia, 29%
with moderate anemia, and 3% with severe anemia [20].
Sadly, the trend of anemia prevalence among Ethiopianchildren declined from 54 to 44% from 2005 to 2011,
but increased to 57% in 2016 [20]. This high prevalence
of anemia in 2016 may be due to iron deficiency is a key
factor of hemoglobin, and iron deficiency is valued to be
responsible for this high prevalence. Other attributes of
anemia include malaria, hookworm and helminthes, nu-
tritional deficiencies and chronic infections. In other
words, although great advances have been made in the
management of childhood HIV/AIDS, its burden con-
tinues to hamper progress in reducing childhood mortal-
ity and morbidity in much of the developing world,
particularly in this region [21].
Nonetheless, there is limited evidence on the preva-
lence of anemia among HIV infected children in
Ethiopia. Similarly, the evidence base on the preva-
lence and effect of HAART on children with HIV/
AIDS and anemia comorbidity still remains inconsis-
tence, uncertain and inconclusive. This may perhaps
be due to paucity of data on the topic, particularly in
HIV infected children. This systematic review and
meta-analysis was therefore aimed to summarize the
contemporary evidence base on the prevalence of
anemia among children with HIV/AIDS and its associ-
ation with HAART in Ethiopia.Methods
Study design and search strategy
Study design
This is a systematic review and meta-analysis of pub-
lished articles on anemia among HIV infected children
below 18 years in Ethiopia.
To identify relevant studies, two authors (FW, SE) ex-
haustively and systematically searched for articles published
in English from 1990 to 2017 in MEDLINE/PubMed,
EMBASE, PsycINFO, Web of Science and Google scholar.
Grey literature and reference lists such as programme re-
ports were also retrieved. We used medical subject head-
ings (MESH), adding terms and keywords from a primary
search to formulate search strategy in these databases. In all
databases, we consumed an interactive process to improve
the search strategy through checking numerous search
terms and including new search terms as new relevant cita-
tions were identified. The keywords included: as “HAART,
children, systematic review, meta-analysis, prevalence, epi-
demiology, human immunodeficiency virus, HIV, Ethiopia,
comorbidity, iron status, anemia”. Boolean operators – ‘OR’
or ‘AND’ – were used. Endnote reference manager software
was utilized to collect and organize search outcomes and
for removal of duplicate articles. Moreover, we followed the
Preferred Reporting of Systematic Reviews and Meta-
Analysis (PRISMA) guideline [22]. Furthermore, the study
period for searching of articles were carried out from the
beginning of August, 2017 until December, 2017.
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The inclusion criteria included both cross-sectional and
cohort studies with baseline measures for the outcome of
interest (anemia in HIV) using a priori criteria. In this con-
text, anemia was defined based on the WHO cutoff point
(hemoglobin less than 11 g/dl) for children below 18 years.
Exclusion criteria
Case reports, case reviews and studies addressing spe-
cific groups such as children with other hemoglobinopa-
thies were excluded.
Data extraction
Two reviewers (FW and SE) screened the downloaded ti-
tles and abstracts using the eligibility criteria. Discus-
sions and mutual consensus were in place when possible
arguments were raised between the two reviewers. The
two reviewers then assessed the full text of potentially
eligible papers. Whenever further information is re-
quired, we made some efforts to contact the author’s by
email. When OR with 95% Confidence Interval (CI) was
not computed in the result, we used numerator and
denominator data and beta coefficients and their stand-
ard errors. The following study characteristics were
extracted: primary author, year of publication, study
area, study design and sample size. The proportion of
anemia was also retrieved from each included study.
Quality appraisal
Articles were assessed for quality, with only high quality
studies included in the analysis. Two reviewers (FW, SE)Fig. 1 Flow chart describing selection of studies for a systematic review anindependently extracted the necessary information from
the relevant articles. Discrepancies were adjudicated or dis-
cussed with coauthors (GD, AAA), whenever appropriate.
Newcastle-Ottawa Scale modified for prevalence studies
methodological quality assessment tool was utilized [23].
For dichotomous data, we extracted the number of partici-
pants with the outcome and the total number sample size.
FW and AAA were involved in conception of the research
questions and design as well as critical review of the paper.
Data analysis
Relevant information about the study area, study design
and study sample were summarized by Microsoft Excel and
then exported to STATA/SE version-14 for further analysis.
The pooled prevalence of anemia was conducted using a
random-effects model with 95% CI. Heterogeneity among
studies was computed using the I2 statistic [24]. The I2 stat-
istic estimates the percentage of total variation across stud-
ies. In this study, forest plots were also utilized to estimate
pooled effect size and weight of each recruited study with
95% CI to show a graphic summary of the data. For meta-
analyses with a minimum of 10 studies, publication bias
was determined based on the visual assessment of the fun-
nel plot [25] and Egger’s test [26]. Sub-group analysis by
study design was employed to resolve the occurrence of
high heterogeneity in the included studies. In an effort to
understand the sources of heterogeneity meta-regressions
were performed on sample size and year of publication.
Meta-regression was used instead of subgroup analyses as it
allows for the use of continuous covariates and permits the
inclusion of more than one covariate at a time.d meta-analysis of HIV-anemia comorbidity among children in Ethiopia
Table 1 Descriptive summary of 12 included studies on the anemia-HIV- comorbidity in children on HAART in Ethiopia
Authors and year Region of study Types of
hospital
Study design Sample size Number of children
with outcome
Prevalence (%) Study quality score
Muluneh A. et al.,2009 [18] Oromia Referral Cross-sectional 64 14 21.87 8
Koye et al.,2012 [44] Amhara Referral cohort 520 103 19.80 7
Kedir et al., 2014 [45] Oromia Referral cohort 522 109 20.88 6
Enawgaw et al.,2015 [46] Amhara Referral Cross-sectional 265 43 16.22 8
Teklemariam et al.,2015 [17] Harer Referral Cross-sectional 66 26 39.39 6
Hylemariam et al.,2015 [16] Addis Ababa Referral Cross-sectional 180 40 22.22 7
Debasu et al.,2015 [47] Addis Ababa Referral Cross-sectional 106 20 18.86 7
Tesfanesh.A,2016 [48] Adis Abeba Referral Cross-sectional 108 19 17.59 8
Tsegay et al.,2017 [49] Amhara Referral Cross-sectional 224 66 29.46 8
Animut et al.,2017 [50] Amhara Referral cohort 538 66 12.26 8
Bitew et al.,2017 [51] Wolaita HC cohort 228 77 33.77 9
Lamessa D.,2017 [52] Addis Ababa hospital cohort 703 168 23.89 7
Table 2 The effect of HAART treatment on HIV/AIDS-anemia
comorbidity
Region Author and year Anemic Non-anemic OR
Oromo Muluneh A.
et al.,2009 [18]












HAART 8 71 0.24
Non-HAART 32 69
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We followed the PRISMA guideline to present the
findings of this review. First, 1013 articles related to
the prevalence of anemia in HIV-positive children
were found. Of these, 30 duplication and 954 unre-
lated articles were excluded. Second, from the
remaining 29 articles, 17 full-text articles were ex-
cluded. Among these, 10 studies [27–36] did not
present relevant findings exclusively for study target
population and, 7 studies were excluded because 1
was incidence study [37], 4 studies [38–41] did not
present outcome of interest and 2 studies [42, 43]
used various hemoglobin cutoff points. Finally, 12 ar-
ticles representing 3524 children living with HIV, met
the inclusion criteria (Fig. 1).
Descriptive summary of the included full-text articles
All the 12 studies representing 3524 children included in
the present review provided data on prevalence of anemia
among HIV infected children. The mean age of partici-
pants was 7.7 years with standard deviation (SD) of +3.3
Years. The prevalence of anemia among individual studies
ranged between 12.3% (in Amhara region) [25] to 39.4%
(in Harer) [17] (Table 1)
Descriptive summary of HAART on anemia-HIV/AIDS
comorbidity
Four studies were included to determine the effect of
HAART on anemia among HIV/AIDS children. These
studies reported OR ranging from 0.2 [16, 18] to 0.5 for
the comorbidity [17] (Table 2).
Comorbidity of anemia-HIV/AIDS in children
The point prevalence of anemia among HIV/AIDS
infected Ethiopian children was 22.3% (95% CI:
18.5–26.1) (Fig. 2). A sub-group analysis by studydesigns also showed similar levels of comorbidity in
these children (Fig. 3). The I2 test indicated high
heterogeneity (I2 = 97.7%, p < 0.001). In an effort to
identify the possible source of heterogeneity, differ-
ent factors associated with the heterogeneity such as
publication year and sample size of the study. These
were investigated by using univariate meta-regression
models, but none of these variables were statistically
significant (Table 3).The pooled effect of HAART on anemia in HIV/AIDS
infected children
Treatment with HAART for children living with HIV/
AIDS was found to decrease the level of anemia by 60%
(OR: 0.4 (95% CI (0.2–0.5)) as compared to non-HAART
initiated children with the disease. Heterogeneity test
showed no statistically significant evidence, p = 0.38
(Fig. 4). Also, the overall Egger’s test for publication bias
revealed no statistically significant evidence, p-value = 0.17
(Additional file 1: Figure S1).
Fig. 2 Forest plot showing the point prevalence of anemia-HIV comorbidity in children in Ethiopia
Fig. 3 Forest plot showing subgroup analysis of anemia-HIV comorbidity in children in Ethiopia by study designs
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Table 3 Related factors with heterogeneity of the anemia-HIV
comorbidity in the current meta-analysis (Based on Univariate
Meta Regression)
Variables Coefficient P-value
Publication year .6539374 0.53
Sample size −.0112698 0.3
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The evidence on the pediatric HIV infection and anemia
is limited because of paucity of data on anemia associ-
ated with HIV infection as well as on the effect of
HAART on the anemia. Using the WHO definition of
pediatric anemia (hemoglobin < 11 g/dl), more than 1 in
5 children living with HIV/AIDS are anemic in Ethiopia.
This finding is in keeping with the global perspective of
the burden of the disease in that mild and moderate
anemia is more prevalent with HIV infection irrespective
of region [53]. Interestingly, however, this finding is
slightly lower than findings from previous studies. For
example, a systematic review and meta-analysis done
by Esan et al. [54] suggested a 34% pooled mean
prevalence of anemia in HIV-infected children. Fur-
thermore, a study of 2919 HIV-positive children from
west Africa shows 40.5% rate of anemia in children
[55]. The observed difference might be attributable to
the differences in sociodemographic characteristics,
study design and study period. Iron, B12 and folic
acid deficiencies, local nutritional status and preva-
lence of parasitic infections such as malaria and/orFig. 4 Forest plot showing the effect of HAART treatment on anemia-HIV chookworm might contribute to the variations in the
prevalence of anemia. Moreover, a possible reason for
the decreased prevalence of anemia in this study
could be attributed to the adoption of the recent
“WHO 90-90-90 test and treat policy” which has seen
many more HIV infected children initiated early on
HAART thereby halting anemia comorbidity [56, 57].
Although investigation into the mechanisms associ-
ated with anemia in HIV patient is beyond the scope
of the current study, it could also be explained by a
decreased production, increased destruction and inef-
fective production of red blood cells. Furthermore,
abnormal nutrient absorption and diseases of the
gastro-intestinal system, particularly in advanced HIV/
AIDS cases, may lead to anemia [58].
This study also showed that HAART significantly re-
duced anemia in children living with HIV/AIDS. That is,
children on HAART are less likely to be anemic as com-
pared to their anemia status before treatment with
HAART is initiated or relative to non-HAART initiated
children. This finding is in line with study done by
Walker et al. (2002) that revealed that the occurrence
of anemia-HIV/AIDS comorbidity was lower in chil-
dren receiving routine HAART as compared to chil-
dren not on HAART [59]. This evidence is also
supported by other previous studies [54, 60–62] that
revealed the prevalence of anemia was higher in HIV
infected children who did not receive HAART. The
capacity of HAART to prevent opportunistic infec-
tions could in some way reduce the negative impactomorbidity in children in Ethiopia
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over, HAART-enhanced hematopoietic progenitor cell
growth may reduce viral load by inhibiting viral repli-
cation [63, 64]. Overall, the findings of this study sug-
gested the importance of HAART to mitigate the
clinical and public health consequences of anemia
among pediatric HIV/AIDS patients.
However, the findings need to be considered in the
context of some important limitations. Even though we
performed subgroup analyses and meta-regression, het-
erogeneity was observed in all analyses. These include
the inclusion of studies published only in English that
may compromise representativeness (due to language
bias). As well, because of heterogeneity across studies
and lack of sufficient number of studies, this study did
not explore other potential factors contributing to
anemia in HIV/AIDS such as the type of HAART, the
length of antiretroviral exposure, presence of opportun-
istic infections and advanced stage of the HIV/AIDS dis-
ease. Future research that considers these variables and
disease characteristics would advance the findings of this
meta-analysis.
Conclusion
Anemia is a common comorbidity in children living with
HIV/AIDS in Ethiopia. HAART initiation was significantly
associated with a reduced anemia-HIV/AIDS comorbidity.
Prompt start of HAART, whenever appropriate, is sug-
gested to decrease the prevalence of the comorbidity and
subsequent complications.
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